IRVINE, Calif. & DELRAY BEACH, Fla.--(BUSINESS WIRE)--Jun. 18, 2018--
Masimo (NASDAQ:
MASI) and Thermomedics, a PositiveID
(OTCQB: PSID) company, announced today the debut and U.S. market release
of TIR-1™, a non-contact Bluetooth®-enabled thermometer that
integrates seamlessly with the Masimo Root® patient
monitoring and connectivity platform.
This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20180618005375/en/
Masimo TIR-1™ (Photo: Business Wire)
TIR-1 is an easy-to-use, clinical-grade infrared thermometer that
provides forehead temperature measurements across all patient
populations. As a non-contact device, the thermometer reduces the
possibility of cross-contamination and eliminates the need to purchase
additional disposables such as probe covers, reducing cost and waste.
Its simple, one-button operation delivers patient temperature results in
seconds, reducing the time needed to take temperature measurements
compared to traditional methods. Bluetooth connectivity, available
exclusively in the customized thermometer developed by Thermomedics for
Masimo, enables wireless data transfer to a connected Root monitor,
automating efficient integration of an important patient vital sign into
bedside devices, including early warning scores, and from there to
hospital EMRs via Masimo Patient SafetyNet™* or Iris Gateway™.
Masimo Root is a powerful, expandable patient monitoring and
connectivity hub that integrates an array of technologies, devices, and
systems to provide multimodal monitoring and connectivity solutions – in
a single, clinician-centric platform. Root’s plug-and-play expansion
capabilities allow clinicians to centralize patient monitoring by
bringing together advanced rainbow SET™ Pulse CO-Oximetry, brain
function monitoring, regional oximetry, capnography, and vital signs
measurements – now including non-contact thermometry – on an
easy-to-interpret, customizable display, empowering clinicians with more
information for making patient assessments.
Joe Kiani, Founder and CEO of Masimo, said, “TIR-1 is a great example of
the powerful expandability and versatility of the Root platform, and of
our commitment to improving patient care through streamlined and
automated workflows. This thermometer makes it easy to efficiently take
the temperatures of multiple patients without having to manually record
data. We’re delighted to have partnered with Thermomedics to develop an
additional, easy-to-use thermometry option for Root customers.”
William J. Caragol, Chairman and CEO of PositiveID, said “Our team
worked diligently to develop the TIR-1, the first Bluetooth-wireless
non-contact thermometer to be paired with a vital signs monitoring
system. We are very proud to bring this product to market with a
world-class company like Masimo and introduce non-contact thermometry to
the Root platform.”
@MasimoInnovates |
#Masimo
*The use of the trademark Patient SafetyNet is under license from
University HealthSystem Consortium.
About Thermomedics/PositiveID
Thermomedics, Inc. designs, develops and markets medical diagnostic
equipment for professional healthcare providers. Our products are
specifically designed for use in a wide range of medical settings,
delivering nearly instantaneous diagnostic information. Our goal was
simple from the start. We wanted to build the best equipment and bring
the most cutting edge technology to frontline medical professionals.
Thermomedics, Inc. is a wholly owned subsidiary of PositiveID
Corporation™ (OTCQB: PSID), a life sciences tools and diagnostics
company. PositiveID specializes in the development of microfluidic
systems in order to detect biological threats and outbreaks, whether
airborne, in a healthcare setting, or at the point of need through its
ExcitePCR subsidiary. For more information on PositiveID, please visit http://www.psidcorp.com,
or connect with PositiveID on Twitter,
Facebook
or LinkedIn.
About Masimo
Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive
monitoring technologies. Our mission is to improve patient outcomes and
reduce the cost of care. In 1995, the company debuted Masimo SET®
Measure-through Motion and Low Perfusion™ pulse oximetry, which has been
shown in multiple studies to significantly reduce false alarms and
accurately monitor for true alarms. Masimo SET® has also been
shown to help clinicians reduce severe retinopathy of prematurity in
neonates,1 improve CCHD screening in newborns,2
and, when used for continuous monitoring with Masimo Patient SafetyNet™*
in post-surgical wards, reduce rapid response activations and costs.3,4,5
Masimo SET® is estimated to be used on more than 100 million
patients in leading hospitals and other healthcare settings around the
world,6 and is the primary pulse oximetry at 17 of the top 20
hospitals listed in the 2017-18 U.S. News and World Report Best
Hospitals Honor Roll.7 In 2005, Masimo introduced rainbow®
Pulse CO-Oximetry technology, allowing noninvasive and continuous
monitoring of blood constituents that previously could only be measured
invasively, including total hemoglobin (SpHb®), oxygen
content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin
(SpMet®), Pleth Variability Index (PVi®), and more
recently, Oxygen Reserve Index (ORi™), in addition to SpO2,
pulse rate, and perfusion index (Pi). In 2014, Masimo introduced Root®,
an intuitive patient monitoring and connectivity platform with the
Masimo Open Connect® (MOC-9®) interface, enabling
other companies to augment Root with new features and measurement
capabilities. Masimo is also taking an active leadership role in mHealth
with products such as the Radius-7® wearable patient monitor,
iSpO2® pulse oximeter for smartphones, and the
MightySat™ fingertip pulse oximeter. Additional information about Masimo
and its products may be found at www.masimo.com.
Published clinical studies on Masimo products can be found at http://www.masimo.com/evidence/featured-studies/feature/.
ORi has not received FDA 510(k) clearance and is not available for sale
in the United States.
*The use of the trademark Patient SafetyNet is under license from
University HealthSystem Consortium.
References
-
Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm
Infants through Changes in Clinical Practice and SpO2
Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
-
de-Wahl Granelli A et al. Impact of pulse oximetry screening on the
detection of duct dependent congenital heart disease: a Swedish
prospective screening study in 39,821 newborns. BMJ. 2009;Jan
8;338.
-
Taenzer AH et al. Impact of Pulse Oximetry Surveillance on Rescue
Events and Intensive Care Unit Transfers: A Before-And-After
Concurrence Study. Anesthesiology. 2010; 112(2):282-287.
-
Taenzer AH et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia
Patient Safety Foundation Newsletter. Spring-Summer 2012.
-
McGrath SP et al. Surveillance Monitoring Management for General Care
Units: Strategy, Design, and Implementation. The Joint Commission
Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
-
Estimate: Masimo data on file.
- http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.
Forward-Looking Statements
This press release includes forward-looking statements as defined in
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, in connection with the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include, among others, statements regarding the potential
effectiveness of Masimo TIR-1™ and Root®. These
forward-looking statements are based on current expectations about
future events affecting us and are subject to risks and uncertainties,
all of which are difficult to predict and many of which are beyond our
control and could cause our actual results to differ materially and
adversely from those expressed in our forward-looking statements as a
result of various risk factors, including, but not limited to: risks
related to our assumptions regarding the repeatability of clinical
results; risks related to our belief that Masimo's unique noninvasive
measurement technologies, including Masimo TIR-1 and Root, contribute to
positive clinical outcomes and patient safety; risks related to our
belief that Masimo noninvasive medical breakthroughs provide
cost-effective solutions and unique advantages; as well as other factors
discussed in the "Risk Factors" section of our most recent reports filed
with the Securities and Exchange Commission ("SEC"), which may be
obtained for free at the SEC's website at www.sec.gov.
Although we believe that the expectations reflected in our
forward-looking statements are reasonable, we do not know whether our
expectations will prove correct. All forward-looking statements included
in this press release are expressly qualified in their entirety by the
foregoing cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or
clarify these statements or the "Risk Factors" contained in our most
recent reports filed with the SEC, whether as a result of new
information, future events or otherwise, except as may be required under
the applicable securities laws.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180618005375/en/
Source: Masimo
Thermomedics/PositiveID
Allison Tomek, 561-805-8044
atomek@psidcorp.com
or
Masimo
Evan
Lamb, 949-396-3376
elamb@masimo.com